GSK plc (GLAXF)
GSK plc is a healthcare company engaged in the research, development, and manufacture of medicines and vaccines. Through its Commercial Operations and Total R&D segments, the company develops specialty medicines, vaccines, and general medicines for use in the United Kingdom, the United States, and other international markets. Its specialty medicines portfolio includes treatments in oncology, respiratory and immunology, inflammation, and inhaled therapies, as well as products for HIV and several other disease areas. GSK also supplies vaccines covering indications such as shingles, meningitis, RSV, influenza, hepatitis, and a range of childhood and infectious diseases. In addition, the company markets general medicines for conditions including asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin disorders. GSK is headquartered in London, United Kingdom, and was formerly known as GlaxoSmithKline plc before adopting its current name in 2022.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-GLAX.F
|
$43.92
|
70.5% Upside
|
Bargain
|
—
|
—
|
—
|
Great
|
—
|
—
|
0.9
|
3.5%
|
July 28, 2026
|
12.9x
|
4.2x
|
2.3x
|
100.6 B
|
118.3 B
|
20.4%
|
96.8%
|
5.6
|
44.5%
|
109.4%
|
